Are there ways to optimize doxorubicin for cancer patients? – New Paper

by Dr. Jeremy Johnson | Posted on

Doxorubicin is a chemotherapy drug that was originally isolated from Streptomyces peucetius var. caesius in the 1970’s and has been used in a variety of cancer treatments including breast, lung, ovarian, thyroid among others cancers.

In this paper we describe how a drug eluting embolic transarterial chemoembolization can benefit the pharmacokinetic properties compared to conventional doxorubicin treatment.

This project was published in the journal Drug delivery and translational research and is titled, “Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.”

You can read the paper here https://pubmed.ncbi.nlm.nih.gov/33861419/

About the author

Dr. Johnson received his PharmD and PhD at the University of Wisconsin where he also completed a clinical research fellowship evaluating phytochemicals and botanical extracts. He is an associate professor and licensed pharmacist he offers a unique perspective on the most current scientific literature related to the health and nutrition. His research program is active and has led to more than 50 publications and published abstracts related to the health promoting properties of natural products, phytochemicals and plant extracts. He has presented some of his research findings at international scientific meetings in the US, Italy, Austria, Israel, France, China, Philippines and Turkey.

Related Posts